China SXT Pharmaceuticals (SXTC) Receivables (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Receivables for 9 consecutive years, with $18.7 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables rose 392.4% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (up 392.4% YoY) and the FY2026 annual result came in at $18.7 million, up 392.4% from the prior year.
• Receivables grew to $18.7 million in Q1 2026 per SXTC's latest filing, from $4.7 million in the prior quarter.
• Over the last five years, Receivables for SXTC reached as high as $18.7 million in Q1 2026 and fell as low as $2.8 million in Q3 2023.
• A 5-year average of $5.8 million and a median of $4.5 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables soared 2412.83% — and 2023, when it sank 58.97%.
• Year by year, Receivables stood at $6.8 million in 2022, then plunged by 58.97% to $2.8 million in 2023, then jumped by 64.19% to $4.5 million in 2024, then gained by 3.61% to $4.7 million in 2025, then jumped by 297.2% to $18.7 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $18.7 million, $4.7 million, and $3.8 million for Q1 2026, Q3 2025, and Q1 2025 respectively.